<DOC>
	<DOCNO>NCT00135018</DOCNO>
	<brief_summary>This study investigate whether cyclooxygenase inhibition celecoxib add benefit preoperative chemotherapy alone breast cancer patient .</brief_summary>
	<brief_title>Study Neoadjuvant Use Chemotherapy Celecoxib Therapy Patients With Invasive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>The patient must free psychiatric addictive disorder mentally able follow prescription instruction able give write informed consent . The patient must consent study must sign approved consent form conform institutional guideline . The patient must age 18 year old . The diagnosis invasive adenocarcinoma breast must confirm core Trucut biopsy interval initial histological diagnosis breast cancer registration must 1 month . The primary tumor within breast must palpable measurable clinical examination ultrasound , must confine one breast . For patient clinically negative axillary node , primary tumor size must 2 7 cm . For patient clinically positive axillary node , primary tumor size 7 cm acceptable ( T23 , N0 , M0 T13 , N1 , M0 ) . ECOG performance status 01 correspond Karnofsky performance status least 70 . Within one month prior time registration , patient must follow : history , physical examination , blood test , tumor estrogen progesterone receptor status assessment , chest Xray , bone scan , abdominal ultrasound , bilateral mammogram , electrocardiogram ( ECG ) . Hematology parameter : white blood cell ( WBC ) least 2500/mm3 ; neutrophil count least 2,000/mm3 ; platelet count least 100,000/mm3 ; hemoglobin least 10g/dL . Other laboratory parameter : total serum bilirubin exceed 2 time institutional upper limit normal ( ULN ) ; AST exceed 2 time ULN ; ALT exceed 2 time ULN ; alkaline phosphatase exceed 2 time ULN ; serum creatinine exceed 2 time ULN . In borderline case , inclusion study leave judgment principal investigator . The patient must adequate ventricular function leave ventricular ejection fraction ( LVEF ) less 55 % echocardiogram scan . Patients prior nonbreast malignancy eligible disease free 5 year receive chemotherapy , immunotherapy , hormonal therapy radiation therapy within last 5 year . Patients curatively treat nonmelanoma skin cancer carcinoma situ cervix eligible even diagnose within last 5 year prior registration . Patients receive sex hormonal therapy e.g. , birth control pill , ovarian hormonal replacement therapy , etc. , eligible therapy discontinue 1 month prior registration . Male patient Patients distant metastasis , include skin involvement beyond breast area . Patients ulceration , erythema infiltration skin ( complete fixation ) , inflammatory breast cancer peau d'orange ( edema ) magnitude . ( Tethering dimple skin nipple inversion interpret skin infiltration patient condition eligible . ) Patients ipsilateral lymph node clinically fix one another structure ( N2 disease ) . Patients mass opposite breast , suspicious malignancy , unless biopsy proof mass malignant . Patients multiple , bilateral breast cancer suspicious palpable node contralateral axilla patient palpable supraclavicular infraclavicular node , unless biopsy proof node involve malignancy . Postmenopausal patient positive estrogen progesterone receptor status negative lymph node involvement . Pregnant woman woman suspect pregnancy time registration lactate woman eligible study . Patients prior history invasive breast cancer ; patient ipsilateral new cancer/recurrence treatment insitu breast cancer ; patient receive prior therapy breast cancer , include chemotherapy , immunotherapy , hormonal therapy radiation therapy . Patients receive prior anthracycline docetaxel therapy malignancy . Patients serious cardiac illness medical condition include , confine : History document congestive heart failure ( CHF ) ; Highrisk uncontrolled arrhythmias ; Angina pectoris require antianginal medication ; Clinically significant valvular heart disease ; Evidence transmural infarction ECG ; Poorly control hypertension ( e.g . systolic &gt; 180mmHg diastolic great 100mmHg ) . Patients abnormality ECG , e.g. , ventricular hypertrophy , even demonstrate adequate ventricular function echocardiogram . Patients active chronic document infection time registration . Patients preexist peripheral neuropathy ( grade 2 great accord National Cancer Institute Adverse Event [ NCI AE ] v 3.0 ) patient risk develop peripheral neuropathy , i.e. , poorly control diabetes mellitus . Patients rheumatic disease patient cyclooxygenase2 inhibitor medication . Patients hepatitis B and/or hepatitis C carrier . Patients know hypersensitivity contraindication study pre medication product formulate polysorbate 80 . Patients judge investigator unfit enrol study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>